UP202-56

UP202-56 is an adenosine analogue, which is an adenosinergic agonist.

Signaling Pathways >> GPCR/G Protein >> Adenosine Receptor

Research Areas >> Inflammation/Immunology

Adenosine Receptor[1][2]

The effects of oral administration of UP202-56, an adenosine analogue, are assessed on carrageenan-induced spinal c-Fos protein expression and peripheral oedema. Oral UP202-56 (10, 30 or 50 mg/kg) dose-dependently reduces the number of carrageenan-induced c-Fos like immunoreactivity (c-Fos-LI) neurons (r=0.931. P<0.0001), with the highest dose of UP202-56 producing 72±4% reduction of the total number of carrageenan-induced spinal c-Fos-LI neurons, and 12±3% and 33±6% of reduction of control carrageenan oedema at paw and ankle levels, respectively. UP202-56 dose-dependently reduces the spinal c-Fos protein expression in carrageenan model of inflammatory pain[1]. UP202-56 is an adenosinergic agonist[2].

[1]. Honoré P, et al. UP 202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression. Pain. 1998 Apr;75(2-3):281-93.

[2]. Camborde, Francois, et al. PHARMACEUTICAL COMBINATION WITH ANALGESIC ACTIVITY, CONTAINING AN ADENOSINERGIC AGONIST AND A COMPOUND SELECTED FROM OPIATES, BENZODIAZEPINES AND NMDA ANTAGONISTS. Patent Application WO/1999/029347.

CGS 21680 hydrochloride | Preladenant | ZM 241385 | CPI-444 | SCH 58261 | Vipadenant | Istradefylline | Tozadenant | AZD-4635 | Capadenoson | 2-CL-IB-MECA | PSB-12379 | CD73-IN-1 | IB-MECA | Diprophylline